Venture Capital

Apogee bags $1.3B royalty funding deal to advance eczema hopeful

Apogee has secured a promise of up to $1.3 billion from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.

James Waldron May 27, 2026 8:57am

With $30M, Oorja Bio breathes new life into fibrosis candidate

May 20, 2026 10:31am

Fierce Biotech Fundraising Tracker '26: Accro, Create & more

May 19, 2026 10:00am

Create Medicines fashions $122M raise for in vivo CAR-T dreams

May 14, 2026 9:42am

Quantinuum vacuum chamber hero quantum computer

Amgen-backed quantum computing firm plans IPO

May 10, 2026 8:25am

Blackstone Invests $250M in Anagram to reduce CF pill burden

May 7, 2026 10:36am